S. 652 · 119th Congress (2025–2027)
Protecting Patients from Deceptive Drug Ads Act
This bill establishes civil penalties for false or misleading communications about prescription drugs by certain entities on social media. It also requires additional disclosures and reporting relating to drug advertisements on social media or via telehealth.
The bill’s civil penalties apply when social media influencers or health care providers make communications regarding prescription drugs, using social media platforms, from which they financially benefit that (1) are made knowingly or recklessly and are false or inaccurate, or (2) fail to include the brief summary information (i.e., side effects, contraindications, effectiveness) required in drug advertisements. The Food and Drug Administration (FDA) must issue guidance and publish notice of such enforcement actions. The FDA may notify drug manufacturers when such communications fail to include the brief summary information.
The bill also requires telehealth providers (i.e., entities that use telecommunications to bring together patients and drug prescribers or dispensers) to include the brief summary information in prescription drug advertisements.
Also, payments from drug manufacturers to health care providers or social media influencers, or from health care providers to influencers, for communications promoting prescription drugs must be reported in accordance with anti-kickback laws for federal health care programs.
Additionally, the FDA may conduct market surveillance regarding prescription drug promotion on social media, including analyzing communications and establishing a task force with the Federal Trade Commission.
Show official title
A bill to provide for the regulation of certain communications regarding prescription drugs.
Referred to committee
Latest actionReferred to committee
This bill’s path
This is S. 652’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed Senate
Passed House
Sent to President
Signed into law
- Sponsor
- Sen. Richard J. Durbin (D-IL)
- Cosponsors
1 cosponsor
1 original · 0 later
- Sen. Roger Marshall (R-KS)· Original · Feb 20, 2025
- Policy area
- Health
- Subjects
- Administrative law and regulatory procedures
- Civil actions and liability
- Congressional oversight
- Department of Health and Human Services
- Government information and archives
- Health technology, devices, supplies
- Internet, web applications, social media
- Manufacturing
2 more
- Marketing and advertising
- Prescription drugs
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in Senate
Document: Introduced in Senate
Sources
- Congress.gov action
- Library of Congress
- Latest
Referred to committee
Congressional Record S1129–S1130
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sources
- Congress.gov action
- Senate
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in Senate |
Titles (2)
Protecting Patients from Deceptive Drug Ads Act
Display title, Short title · Introduced in Senate
A bill to provide for the regulation of certain communications regarding prescription drugs.
Official title · Introduced in Senate